Paper
0
Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
Authors
Journal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.